Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Yasser Zaghloul

Yasser Zaghloul

Sheikh Khalifa Medical City

Title: Heart failure in non-cardiac surgery patients

Biography

Biography: Yasser Zaghloul

Abstract

The prevalence of Heart Failure (HF) in the general population continues to grow. Meanwhile, the risk of perioperative HF increases with major surgery, elderly patients, vascular surgery and in the presence of a systemic disease. Th is makes HF one of the most common conditions requiring evaluation and treatment in the perioperative period. HF is considered a major risk factor for development of postoperative cardiac complications e.g. ischemia, infarction and cardiac death. Moreover, some patients may develop HF without structure heart disease like in cases of hypertension, diabetes mellitus, obesity, metabolic syndrome and sepsis. HF is associated with signifi cant neurohormonal changes and activation of sympathetic nervous system. In addition to the systemic perioperative changes e.g. stress response, blood loss and hypoxaemia, all result in increase in the complexity of the patho-physiology and management. Th ere are many causes which contribute in the pathogenesis of HF e.g. impaired contractility, systolic and or diastolic dysfunction, obstructive and regurgitated vavular disease, rate and rhythm abnormalities and pulmonary diseases. In the perioperative sitting, HF should be diff erentiated from other causes of pulmonary edema which may occur in patients without cardiac problems e.g. fl uid overload and neurogenic pulmonary edema. In patients with chronic HF, perioperative and anesthetic management should focus on prevention and treatment of factors which may precipitate acute de-compensation e.g. discontinuation of therapy, sympathetic activity, myocardial ischemia, anemia, volume overload, arrhythmias and poor pain management. Patients with diagnosed HF should continue their cardiac medications during the perioperative period. Th ese include anti-hypertensive, ant-ischemic, anti-arrhythmic and ant-failure medications. In conclusion, HF is an important predictor of adverse outcome; it increases the risk of operative mortality and hospital readmission. Improvements in perioperative care are needed to minimize the risk of heart failure and its consequences.